Treatment with LL28 also showed dose-dependent suppression of IGF1R, Src, and their downstream mediators, including FAK, MEK, and Akt, in A549, H1299, and H460 NSCLC cells (Fig. 2b and c). Here, MAP2K7 is linked to non-small cell lung carcinoma.